Sales going no where fast. Problem here is until TAVR gets into human trials or completes them I can’t see anyone wanting to partner. If that’s the case we have years of “ non dilutive funding” ahead of us, or if that’s not possible dilutive funding. IMO
Ann: Appendix 4C - quarterly, page-9
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |